Form 4: Enliven Therapeutics CFO Benjamin Hohl Executes Option Exercise and Stock Sale

Benjamin Hohl, CFO of Enliven Therapeutics, exercised stock options and sold shares on July 31, 2024, according to a Form 4 filing with the SEC.

Summary

• On July 31, 2024, Benjamin Hohl, the Chief Financial Officer of Enliven Therapeutics, exercised options to purchase 991 shares of common stock at a price of $2.48 per share.
• Simultaneously, Hohl sold 991 shares of Enliven Therapeutics common stock at a weighted average price of $27.5287, with individual sales ranging from $27.50 to $27.655.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 26, 2023.
• Following these transactions, Hohl directly owns 0 shares of Enliven Therapeutics.
• Hohl still holds options to purchase 203,379 shares of common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports transactions by an officer. The use of a 10b5-1 plan suggests pre-planned activity, reducing potential negative interpretations.

Industry Context

Form 4 filings are a routine part of the financial markets, providing transparency into the transactions of company insiders. Investors often monitor these filings to gain insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, potentially creating slight downward pressure on the stock price due to the sale of shares.

Key Dates